Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
High-dose keverprazan regimens for Helicobacter pylori eradication
ChiCTR2500110714Phase 4Not yet recruiting
- Sponsor
- Qilu Hospital of Shandong University
- Start
- Oct 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of keverprazan in Helicobacter pylori infection (3 arms), sponsored by Qilu Hospital of Shandong University. Primary endpoint: Eradication rate of Helicobacter pylori. Planned start Oct 2025; status: not yet recruiting.
02
Drugs
keverprazan
03
Conditions
Helicobacter pylori infection
Beyond the preview
Go deeper on ChiCTR2500110714.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500110714.